Your session is about to expire
← Back to Search
Other
Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19
N/A
Waitlist Available
Research Sponsored by Arizona State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline at day 28
Summary
This trial tests if natural supplements PEA and curcumin can help adults with mild or no COVID-19 symptoms by reducing inflammation, which may prevent the disease from worsening. Curcumin has been proposed as a potential treatment option for COVID-19 due to its anti-inflammatory and antiviral properties.
Eligible Conditions
- Inflammation and Pain
- Inflammation
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline at day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at day 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
IL6 concentration
Secondary study objectives
serum CRP concentration
serum ICAM concentration
serum NFk-beta concentration
+3 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: palmitoylethanolamideExperimental Treatment1 Intervention
Levagen
Group II: HydroCurcExperimental Treatment1 Intervention
curcumin
Group III: PlaceboPlacebo Group1 Intervention
microcrystalline cellulose
Group IV: ControlPlacebo Group1 Intervention
microcrystalline cellulose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Curcumin
2017
Completed Phase 4
~1070
palmitoylethanolamide
2020
N/A
~130
Find a Location
Who is running the clinical trial?
Arizona State UniversityLead Sponsor
301 Previous Clinical Trials
107,935 Total Patients Enrolled